 Pharmacogenetics
"Pharmacogenetics" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A branch of genetics which deals with the genetic variability in individual responses to drugs and drug metabolism (BIOTRANSFORMATION).
| Descriptor ID |
D010597
|
| MeSH Number(s) |
H01.158.273.343.750 H01.158.703.052 H02.628.479
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pharmacogenetics".
Below are MeSH descriptors whose meaning is more specific than "Pharmacogenetics".
This graph shows the total number of publications written about "Pharmacogenetics" by people in this website by year, and whether "Pharmacogenetics" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 | | 1999 | 1 | 0 | 1 | | 2001 | 1 | 0 | 1 | | 2002 | 1 | 1 | 2 | | 2003 | 1 | 0 | 1 | | 2004 | 1 | 1 | 2 | | 2006 | 0 | 2 | 2 | | 2007 | 2 | 0 | 2 | | 2008 | 2 | 2 | 4 | | 2009 | 5 | 3 | 8 | | 2010 | 5 | 3 | 8 | | 2011 | 2 | 5 | 7 | | 2012 | 2 | 5 | 7 | | 2013 | 3 | 6 | 9 | | 2014 | 3 | 7 | 10 | | 2015 | 4 | 2 | 6 | | 2016 | 2 | 3 | 5 | | 2017 | 3 | 2 | 5 | | 2018 | 5 | 4 | 9 | | 2019 | 8 | 5 | 13 | | 2020 | 4 | 4 | 8 | | 2021 | 10 | 4 | 14 | | 2022 | 2 | 5 | 7 | | 2023 | 4 | 4 | 8 | | 2024 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Pharmacogenetics" by people in Profiles.
-
Honeycutt DC, Blom TJ, Ramsey LB, Strawn JR, Bruns KM, Welge JA, Patino LR, Singh MK, DelBello MP. Pharmacogenetic Factors Influence Escitalopram Pharmacokinetics and Adverse Events in Youth with a Family History of Bipolar Disorder: A Preliminary Study. J Child Adolesc Psychopharmacol. 2024 02; 34(1):42-51.
-
Stancil SL, Sandritter T, Strawn JR. Pharmacogenetics and Oxcarbazepine in Children and Adolescents: Beyond HLA-B*15:02. J Child Adolesc Psychopharmacol. 2024 02; 34(1):61-66.
-
Cramer EY, Bartlett J, Chan ER, Gaedigk A, Ratsimbasoa AC, Mehlotra RK, Williams SM, Zimmerman PA. Pharmacogenomic variation in the Malagasy population: implications for the antimalarial drug primaquine metabolism. Pharmacogenomics. 2023 07; 24(11):583-597.
-
Pratt VM, Cavallari LH, Fulmer ML, Gaedigk A, Hachad H, Ji Y, Kalman LV, Ly RC, Moyer AM, Scott SA, van Schaik RHN, Whirl-Carrillo M, Weck KE. CYP3A4 and CYP3A5 Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase. J Mol Diagn. 2023 09; 25(9):619-629.
-
Ramsey LB, Prows CA, Tang Girdwood S, Van Driest S. Current Practices in Pharmacogenomics. Pediatr Clin North Am. 2023 10; 70(5):995-1011.
-
Ramsey LB, Prows CA, Chidambaran V, Sadhasivam S, Quinn CT, Teusink-Cross A, Tang Girdwood S, Dawson DB, Vinks AA, Glauser TA. Implementation of CYP2D6-guided opioid therapy at Cincinnati Children's Hospital Medical Center. Am J Health Syst Pharm. 2023 06 22; 80(13):852-859.
-
Bousman CA, Stevenson JM, Ramsey LB, Sangkuhl K, Hicks JK, Strawn JR, Singh AB, Rua?o G, Mueller DJ, Tsermpini EE, Brown JT, Bell GC, Leeder JS, Gaedigk A, Scott SA, Klein TE, Caudle KE, Bishop JR. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023 07; 114(1):51-68.
-
Kehinde O, Ramsey LB, Gaedigk A, Oni-Orisan A. Advancing CYP2D6 Pharmacogenetics through a Pharmacoequity Lens. Clin Pharmacol Ther. 2023 07; 114(1):69-76.
-
Chevalier R, Attard T, Van Driest SL, Shakhnovich V. A fresh look at proton pump inhibitor (PPI)-associated adverse events through a CYP2C19 pharmacogenetic lens. Expert Opin Drug Metab Toxicol. 2023 02; 19(2):53-56.
-
Bunka M, Wong G, Kim D, Edwards L, Austin J, Doyle-Waters MM, Gaedigk A, Bryan S. Evaluating treatment outcomes in pharmacogenomic-guided care for major depression: A rapid review and meta-analysis. Psychiatry Res. 2023 03; 321:115102.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|